Clinical trial
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN…
NCT00161954 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161954 |
|---|---|
| Title | Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years |
| Official title | Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Encephalitis, Tick-borne |
| Intervention type | Biological |
| Interventions | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
| Start date | Mar 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Sep 13, 2005 |
| Last update posted | May 21, 2015 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: